Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.01
+0.42 (7.51%)
At close: May 12, 2025, 4:00 PM
6.00
-0.01 (-0.17%)
After-hours: May 12, 2025, 7:58 PM EDT
Altimmune Revenue
In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%. Altimmune had revenue of $5.00K in the quarter ending December 31, 2024, a decrease of -86.49%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.31%
P/S Ratio
23,142.60
Revenue / Employee
$339
Employees
59
Market Cap
462.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALT News
- 4 days ago - Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - GlobeNewsWire
- 6 days ago - Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - GlobeNewsWire
- 11 days ago - Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - GlobeNewsWire
- 12 days ago - Altimmune to Participate in the Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine - Seeking Alpha
- 2 months ago - Altimmune to test obesity drug for alcohol use disorder and related health conditions - Reuters
- 2 months ago - Altimmune to Host Virtual R&D Day on March 13, 2025 - GlobeNewsWire
- 2 months ago - Altimmune to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire